Glabralide B is primarily investigated for its anti-inflammatory and immunomodulatory properties. It shows potential in reducing pro-inflammatory cytokines, making it a candidate for development in treating chronic inflammatory conditions such as arthritis and dermatitis. Research also indicates activity in inhibiting certain signaling pathways involved in autoimmune responses, suggesting possible use in autoimmune disease management. Additionally, Glabralide B has demonstrated mild antioxidant effects, which may support its role in protective therapies against oxidative stress-related tissue damage. Studies are ongoing to evaluate its bioavailability and efficacy in topical and oral formulations.